Publish in this journal
Journal Information
Vol. 55. Issue 10.
Pages 1106-1107 (October 2002)
Full text access
Factor xiII Val34Leu Polymorphism and Premature Myocardial Infarction
Polimorfismo Val34Leu del factor xiII e infarto de miocardio prematuro
Visits
...
Francisco Marína, Vanessa Roldánb, Francisco Sogorbc
a Servicio de Cardiología. Hospital General Universitario de Alicante.
b Unidad de Hematología. Hospital de San Vicente. Alicante. España.
c Hospital de San Vicente. Alicante. España.
This item has received
...
Visits
(Daily data update)
Article information
Full Text
Bibliography
Download PDF
Statistics
Full Text

To the Editor:

We read with real interest the exhaustive review by Professor Navarro of genetic polymorphisms and coronary artery disease.1 Nonetheless, we would like to further discuss the influence on myocardial infarction of the Val34Leu polymorphism of coagulation factor XIII (FXIII). This polymorphism conditions a change of valine for leucine only 3 amino acids from the site of activation by thrombin. It has been confirmed that it facilitates the activation of FXIII, increasing and accelerating the stabilization of fibrin.2 Nevertheless, paradoxically, it is has been observed that this polymorphism could play a protective role against both venous and arterial thrombosis,3 as Professor Navarro indicates in his review.1

We studied the Val34Leu genotype of FXIII in 180 patients who suffered myocardial infarction before the age of 45 years and in 585 controls.4 We found that the frequency of the Leu/Leu genotype was greater in patients (7.5% vs 3.8%; P=.05). After adjustment for other cardiovascular risk factors, this genotype was found to be an independent risk factor for the development of premature infarction (P=.019; odds ratio [OR], 3.54; 95% confidence interval [CI], 1.22-10.22).

Recently we analyzed the possible influence of this polymorphism on response to fibrinolytic treatment in premature myocardial infarction.5 We observed that patients with the Val/Val genotype more frequently met criteria for non-invasive reperfusion (P=.006; OR, 5.11; 95% CI, 1.28-21.12). Therefore, the results of our study demonstrate the existence of clinical manifestations of the type suggested by the results of experimental studies.6 These findings enhance the interest of this polymorphism in myocardial infarction and should be examined in prospective multicenter studies. It is even more important to know the influence this polymorphism has on fibrinolytic treatment in populations where it has been shown to be a mutation that protects against the development of thrombotic phenomena.

Bibliography
[1]
Navarro-López F..
Bases genéticas de la enfermedad coronaria..
Rev Esp Cardiol, 55 (2002), pp. 413-31
[2]
Ariens RA.S, Philippou H, Nagaswami C, Weisel JW, Lane DA, Grant PJ..
The factor XIII V34L polymorphism accelerates thrombin activation of factor XIII and affects cross-linked fibrin structure..
Blood, 96 (2000), pp. 988-95
[3]
Kohler HP, Stickland MH, Ossei-Gerning N, Carter A, Mikkola H, Grant PJ..
Association of a common polymorphism in the factor XIII gene with myocardial infarction..
Thromb Haemost, 79 (1998), pp. 8-13
[4]
Marín F, Roldán V, González-Conejero R, Corral J, Pineda J, Climent V, et al..
Polimorfismo genético Val34Leu del factor XIII y riesgo de infarto agudo de miocardio precoz [resumen]..
Rev Esp Cardiol, 54 (2001), pp. 40
[5]
Roldán V, Corral J, Marín F, Rivera J, Vicente V..
Effect of factor XIII Val34Leu polymorphism on thrombolytic therapy in premature myocardial infarction..
Thromb Haemost, 88 (2002), pp. 354-5
[6]
Reed GL, Houng AK..
The contribution of activated Factor XIII to fibrinolytic resistence in experimental pulmonary embolism..
Circulation, 99 (1999), pp. 299-304
Idiomas
Revista Española de Cardiología (English Edition)

Subscribe to our newsletter

Article options
Tools
es en

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?